These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 36796877)

  • 1. Regulatory implications of ctDNA in immuno-oncology for solid tumors.
    Vellanki PJ; Ghosh S; Pathak A; Fusco MJ; Bloomquist EW; Tang S; Singh H; Philip R; Pazdur R; Beaver JA
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
    Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
    Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
    Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
    Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
    Kasi PM; Fehringer G; Taniguchi H; Starling N; Nakamura Y; Kotani D; Powles T; Li BT; Pusztai L; Aushev VN; Kalashnikova E; Sharma S; Malhotra M; Demko ZP; Aleshin A; Rodriguez A; Billings PR; Grothey A; Taieb J; Cunningham D; Yoshino T; Kopetz S
    JCO Precis Oncol; 2022 Mar; 6():e2100181. PubMed ID: 35263168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
    Moding EJ; Nabet BY; Alizadeh AA; Diehn M
    Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA: current challenges for clinical utility.
    Dang DK; Park BH
    J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
    Cherng HJ; Herrera A
    Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
    Sahin IH; Lin Y; Yothers G; Lucas PC; Deming D; George TJ; Kopetz S; Lieu CH; Dasari A
    Oncology (Williston Park); 2022 Oct; 36(10):604-608. PubMed ID: 36260786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
    Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
    Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer.
    Oliveira KCS; Ramos IB; Silva JMC; Barra WF; Riggins GJ; Palande V; Pinho CT; Frenkel-Morgenstern M; Santos SEB; Assumpcao PP; Burbano RR; Calcagno DQ
    Mol Cancer Res; 2020 Apr; 18(4):517-528. PubMed ID: 31996469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
    Chen H; Zhou Q
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
    Malla M; Loree JM; Kasi PM; Parikh AR
    J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
    Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
    J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
    Peng Y; Mei W; Ma K; Zeng C
    Front Oncol; 2021; 11():763790. PubMed ID: 34868984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
    Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.